GENFIT: 2017 Half-Year Results: Cash Position At End Of Period At €126M And Significant Advances In The Company's Pipeline
Published: Sep 25, 2017
Lille (France), Cambridge (Massachusetts, United States), September 25, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical group at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces its financial results for the 2017 half-year. It's 2017 half year business and financial report was made available to the public and filed with the Autorité des marchés financiers ("AMF") today. A summary of the consolidated financial statements is included in this press release. The 2017 half-year consolidated financial statements are available on the "Investors" page of the GENFIT website.